Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 1021 AL 1035

Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis

Qiao Y, Gu J, Yu M, Chi Y, Ma Y.

CNS Drugs. 2024 Mar;38(3):169-192. doi: 10.1007/s40263-024-01067-2. Epub 2024 Mar 1.

Development of dietary small molecules as multi-targeting treatment strategies for Alzheimer's disease

Balakrishnan R, Jannat K, Choi DK.

Redox Biol. 2024 May;71:103105. doi: 10.1016/j.redox.2024.103105. Epub 2024 Mar 4.

Recent Aspects of Periodontitis and Alzheimer's Disease-A Narrative Review

Cichońska D, Mazuś M, Kusiak A.

Int J Mol Sci. 2024 Feb 23;25(5):2612. doi: 10.3390/ijms25052612.

Agmatine as a novel intervention for Alzheimer's disease: Pathological insights and cognitive benefits

Katariya RA, Sammeta SS, Kale MB, Kotagale NR, Umekar MJ, Taksande BG.

Ageing Res Rev. 2024 Apr;96:102269. doi: 10.1016/j.arr.2024.102269. Epub 2024 Mar 11.

Alzheimer's drugs, APPlication for Down syndrome?

Sokol DK, Lahiri DK.

Ageing Res Rev. 2024 Apr;96:102281. doi: 10.1016/j.arr.2024.102281. Epub 2024 Mar 19.

Profiling lecanemab as a treatment option for Alzheimer's disease

Schiller ER, Silverglate BD, Grossberg GT.

Expert Rev Neurother. 2024 May;24(5):433-441. doi: 10.1080/14737175.2024.2333970. Epub 2024 Apr 3.

Personalized, Precision Medicine to Cure Alzheimer's Dementia: Approach #1

Fessel J.

Int J Mol Sci. 2024 Mar 31;25(7):3909. doi: 10.3390/ijms25073909.

[Role of NLRP3 inflammasome in prevention and treatment of cognitive impairment-related diseases and traditional Chinese medicine intervention: a review]

Wang CH, Wei XT, Zhao YQ, Wang DH, Xue JJ, Song ZQ, Tang F, Liu RX, Wang CA.

Zhongguo Zhong Yao Za Zhi. 2024 Feb;49(4):902-911. doi: 10.19540/j.cnki.cjcmm.20230913.403.

Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study

Wisch JK, McKay NS, Boerwinkle AH, Kennedy J, Flores S, Handen BL, Christian BT, Head E, Mapstone M, Rafii MS, O'Bryant SE, Price JC, Laymon CM, Krinsky-McHale SJ, Lai F, Rosas HD, Hartley SL, Zaman S, Lott IT, Tudorascu D, Zammit M, Brickman AM, Lee JH, Bird TD, Cohen A, Chrem P, Daniels A, Chhatwal JP, Cruchaga C, Ibanez L, Jucker M, Karch CM, Day GS, Lee JH, Levin J, Llibre-Guerra J, Li Y, Lopera F, Roh JH, Ringman JM, Supnet-Bell C, van Dyck CH, Xiong C, Wang G, Morris JC, McDade E, Bateman RJ, Benzinger TLS, Gordon BA, Ances BM; Alzheimer's Biomarker Consortium-Down syndrome; Dominantly Inherited Alzheimer Network.

Lancet Neurol. 2024 May;23(5):500-510. doi: 10.1016/S1474-4422(24)00084-X.

Effect and Mechanism of Rapamycin on Cognitive Deficits in Animal Models of Alzheimer's Disease: A Systematic Review and Meta-analysis of Preclinical Studies

Cai J, Xie D, Kong F, Zhai Z, Zhu Z, Zhao Y, Xu Y, Sun T.

J Alzheimers Dis. 2024;99(1):53-84. doi: 10.3233/JAD-231249.

The advent of Alzheimer treatments will change the trajectory of human aging

Selkoe DJ.

Nat Aging. 2024 Apr;4(4):453-463. doi: 10.1038/s43587-024-00611-5. Epub 2024 Apr 19.

Risk of Dementia and Alzheimer's Disease Associated With Antidiabetics: A Bayesian Network Meta-Analysis

Sunwoo Y, Park J, Choi CY, Shin S, Choi YJ.

Am J Prev Med. 2024 Sep;67(3):434-443. doi: 10.1016/j.amepre.2024.04.014. Epub 2024 May 4.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias